The Service of the Commission for the Protection of Competition has received a notification of a concentration according to Section 10 (4) of the Control of Concentrations between Enterprises Law of 2014, concerning the acquisition of the cephalosporin antibiotics business of GlaxoSmithKline plc (hereafter the ‘Target’) by Sandoz AG (hereafter ‘Sandoz’).
Sandoz is a company duly registered in accordance with the laws of the Canton of Basil of Switzerland. Sandoz a Novartis AG division (hereafter ‘Novartis’) which is active in the manufacturing of generic pharmaceuticals and biosimilars mainly in the generic antibiotics and oncology medicines.
Novartis is company based in Switzerland and is active globally in the health care industry and the distribution and trade of medical products.
The Target is the cephalosporin antibiotics business of GlaxoSmithKline. The Target includes the established brands global rights to three established brands Zinnat®, Zinacef® and Fortum® of GSK and the related agreements with customers, suppliers and intellectual property rights, distribution licences and business records.